Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06232876 · ClinicalTrials.gov registry record · NA
Continuous Versus Intermittent Ward Monitoring
A NA study, sponsored by The University of Texas Health Science Center, Houston.
- Not yet
- Registry status
- NA
- Development phase
- 492
- Enrollment target
NCT06232876: Clinical Trial NA study, sponsored by The University of Texas Health Science Center, Houston.
NCT06232876 is a NA study that has not yet begun recruiting, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 492 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (65% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06232876, a NA study, has not yet begun recruiting, sponsored by The University of Texas Health Science Center, Houston.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 492 participants
- Enrollment target
Study Summary
The investigators will randomize adults having major non-cardiac inpatient surgery to blinded versus unblinded continuous postoperative vital sign monitoring (saturation, ventilation, and heart rate). The investigators will use a wearable, untethered, and battery-powered sensor (Masimo Radius PPG, Masimo, Irvine, CA) that wirelessly connects to a Masimo monitor and continuously records saturation, ventilation, and pulse rate. The primary outcome will be areas-exceeding-thresholds for desaturation (\<85%), bradypnea (\<7 breaths/min), tachypnea (\>30 breaths/min), tachycardia (heart rate \>130 beats/min), and bradycardia (heart rate \<45 beats/min). These exposure thresholds represent a balance between events that are clinically meaningful and excessive alarms that will discourage clinician participation. The investigators expect about 1 alert per patient per day with these thresholds, with most being considered informative or actionable by nurses. In unblinded patients, clinician alerts will be activated at these thresholds.
Primary Outcome
Area of vital sign abnormalities exceeding defined thresholds.
Interventions
- DEVICE Blinded continuous vital sign monitoring
- DEVICE Unblinded continuous vital sign monitoring
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 492 participants |
| Start Date | 2026-06-01 |
| Est. Completion | 2029-03-01 |
| Phase | NA |
What is known before NCT06232876 opens enrollment
NCT06232876 is an interventional study that assigns participants to a tested intervention. The registered 492 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (65% lower).
The record links to 0 conditions, and to 2 interventions - of which Blinded continuous vital sign monitoring is the first listed.
NCT06232876 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06232876 about?
NCT06232876 is a clinical study titled "Continuous Versus Intermittent Ward Monitoring". The investigators will randomize adults having major non-cardiac inpatient surgery to blinded versus unblinded continuous postoperative vital sign monitoring (saturation, ventilation, and heart rate). The investigators will use a wearable, untethered, and battery-powered sensor (Masimo Radius PPG, M...
What is the current status of trial NCT06232876?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 492 participants. The study started on 2026-06-01. Estimated completion is 2029-03-01.
What interventions are being tested in trial NCT06232876?
The interventions under investigation include: Blinded continuous vital sign monitoring (DEVICE), Unblinded continuous vital sign monitoring (DEVICE).
Who is sponsoring clinical trial NCT06232876?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06232876's enrollment target sits among peer trials
492 213th of 2000 higher than 1,786 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05861973 · 492 participants · NA
SMARTer Weight Loss Management
- NCT05908331 · 492 participants · NA
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
- NCT06152575 · 492 participants · Phase 3
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- NCT06953089 · 492 participants · Phase 2
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI